Ionis Pharmaceuticals, Inc. Increase (Decrease) in Income Taxes Payable
Ionis Pharmaceuticals, Inc. (IONS) reported Increase (Decrease) in Income Taxes Payable of $164.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. increase (decrease) in income taxes payable for the quarter ending 2026-06-30 was $3.00K.
- Ionis Pharmaceuticals, Inc. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was $161.00K, a 75.00% increase year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was $20.00K.
- Ionis Pharmaceuticals, Inc. increase (decrease) in income taxes payable for the quarter ending 2025-06-30 was -$45.00K, a 100.37% decline year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in income taxes payable for fiscal 2010 was -$7.18M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in income taxes payable for fiscal 2009 was -$10.01M.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 3 month as first filed | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $164.00K 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | $161.00K 10-Q · filed 2026-04-29 | ||||
| 2025-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$25.00K derived: sum of 2 quarters · filed 2026-07-29 | $67.00K 10-Q · filed 2025-10-29 | ||
| 2025-06-30 | -$45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $47.00K 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | $92.00K 10-Q · filed 2026-04-29 | -$25.97M 10-Q · filed 2025-04-30 | |||
| 2024-09-30 | -$243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $11.76M derived: sum of 2 quarters · filed 2025-10-29 | -$2.11M 10-Q · filed 2025-10-29 | ||
| 2024-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$1.87M 10-Q · filed 2025-07-30 | |||
| 2024-03-31 | -$13.87M 10-Q · filed 2025-04-30 | $59.00K 10-Q · filed 2024-05-07 | |||
| 2023-09-30 | $6.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $13.78M derived: sum of 2 quarters · filed 2024-11-06 | $24.82M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $7.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $18.48M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $11.04M 10-Q · filed 2024-05-07 | ||||
| 2022-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$885.00K derived: sum of 2 quarters · filed 2023-11-02 | -$20.00K 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | -$887.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$22.00K 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $865.00K 10-Q · filed 2023-05-03 | ||||
| 2021-09-30 | -$417.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $132.00K derived: sum of 2 quarters · filed 2022-11-09 | $134.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $549.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $551.00K 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $2.00K 10-Q · filed 2022-05-04 | ||||
| 2020-09-30 | -$19.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$23.14M derived: sum of 2 quarters · filed 2021-11-03 | -$23.67M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$4.57M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | -$532.00K 10-Q · filed 2021-05-05 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-04 | ||||
| 2010-12-31 | -$7.18M 10-K · filed 2013-02-28 | ||||
| 2009-12-31 | -$10.01M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |